Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE)

Prior treatment

• Patient who already received 2 medical treatment lines
• Planned concomitant participation to another medical interventional trial during the 12 months following the inclusion in the randomized study PREPARE
• Previous enrolment in the present study

Other illness

• Exclusive 1st or 2nd treatment lines of :
  • Hormonotherapy (except for prostate cancer : abiteratone acetate is allowed),
  • Surgery,
  • Radiotherapy,

Other

• "Best supportive care" treatment
• Patient unable to understand quality of life questionnaire
• Patient unable to follow and comply with the study procedures because of any geographical, social or psychological reasons.
• Patient placed under guardianship

• Patient older 70 years and older
• Performance status 0 to 3 (WHO)
• G8 and QLQ-C30 questionnaires 'score are available
• No previous geriatric evaluation during cancer treatment
• Locally advanced or metastatic disease :
  • 1st line medical treatment :
  • Breast cancer : locally advanced or metastatic disease, hormone-resistant and Her2 negative,
  • Colon and rectum : metastatic (unresectable metastasis),
  • Prostate cancer : metastatic and refractory to hormonal castration,
  • Bladder cancer : locally advanced or metastatic,
  • Ovarian cancer : advanced stage (IIb to IV),
  • Lung cancer : metastatic non-small cell,
  • Lymphomas (indolent and aggressive)
  • Or 2nd line medical treatment :
  • Breast cancer : locally advanced or metastatic disease, hormone-resistant and Her2 negative,
  • Colon and rectum : metastatic (unresectable metastasis),
  • Prostate cancer : metastatic and refractory to hormonal castration,
  • Ovarian cancer : advanced stage (IIb to IV),
  • Lymphomas (indolent and aggressive)
• Life expectancy over 6 months
• Signed informed consent
• Patients with a French social security in compliance with the French law relating to biomedical research (Article L.1121-11 of French Public Health Code).